NEW YORK (GenomeWeb News) – Biosimulation firm Entelos said today that it expects its fourth-quarter and full-year revenues to be below previous estimates.
 
“The current economic crisis has impacted almost every industry including our customer segment,” Entelos said in a statement. “Many of our pharmaceutical customers have recently announced delays in some of their internal drug development programs.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.